Clinical Trials Logo

Filter by:
NCT ID: NCT05269056 Recruiting - Clinical trials for Early Gastric Cancer

Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics

Start date: September 1, 2021
Phase:
Study type: Observational

The purpose of this study is to enable non-invasive early detection of gastric cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage gastric cancer patients and healthy individuals will be subjected to whole-genome sequencing. Features, such as cell-free DNA fragmentation, copy number variations and microbiome, will be assessed to generate this model.

NCT ID: NCT05268718 Recruiting - Clinical trials for Keratitis, Ulcerative

Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis

Start date: August 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical study was conducted to evaluate the efficacy and safety of gold-silver cuprous oxide composite nanogels combined with photothermal therapy system in the treatment of severe drug-resistant bacterial keratitis ineffective by traditional antibiotic treatment in human eyes, and to provide translational applications. Based on the clinical evidence, a more effective and safe innovative treatment plan for corneal diseases has been developed.

NCT ID: NCT05268289 Recruiting - Lupus Nephritis Clinical Trials

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Start date: August 10, 2022
Phase: Phase 2
Study type: Interventional

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

NCT ID: NCT05268172 Recruiting - Clinical trials for Pleural Effusion, Malignant

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Start date: December 20, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.

NCT ID: NCT05267678 Recruiting - Clinical trials for Recurrent Miscarriage

Nutritional Deficiency and Recurrent Miscarriage

Start date: January 28, 2023
Phase:
Study type: Observational

This prospective cohort study primarily aims to examine the association between blood niacin levels and recurrent miscarriage.

NCT ID: NCT05267366 Recruiting - PFS Clinical Trials

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival in NSCLC by the study of KEYNOTE 024, KEYNOTE 189 etc. Thus, this study combines immunotherapeutic agent PD-1 inhibitor with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin/cisplatin and pemetrexed).

NCT ID: NCT05267288 Recruiting - PFS Clinical Trials

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

There is no report afatinib plus bevacizumab in the treatment of EGFR G719X, S768I, and L861Q single or compond mutation of metastatic non-small-cell lung cancer (NSCLC). The purpose of this study is to study afatinib combined with bevacizumab in the management of it.

NCT ID: NCT05267275 Recruiting - Clinical trials for the Incidence of Complications Related to Rectal Anastomosis After Neoadjuvant Therapy

Extended Resection for Rectal Cancer With Neoadjuvant Radiotherapy

Start date: November 30, 2021
Phase: N/A
Study type: Interventional

Preoperative neoadjuvant therapy has become the guideline-recommended standard treatment for patients with locally advanced or mid-to-low rectal cancer with suspected regional lymph node metastasis. However, preoperative neoadjuvant radiotherapy caused radiation damage to the pelvic bowel, resulting in varying degrees of edema, vascular stiffness, and insufficient blood supply. According to the traditional rectal cancer surgery, the proximal bowel resection only needs to be more than 10cm above the upper edge of the tumor. However, this range of resection cannot remove all the damaged proximal bowel, and using the damaged proximal bowel for anastomosis may lead to the risk of anastomotic-related complications (including anastomotic leakage, anastomotic stenosis, and anastomotic proximal bowel stiffness, etc.) also increased. Therefore, extended resection of the proximal bowel with splenic flexure mobilization and using healthy proximal bowel for anastomosis may help reduce the incidence of complications related to rectal anastomosis after neoadjuvant therapy.

NCT ID: NCT05267093 Recruiting - Hand Osteoarthritis Clinical Trials

Acupuncture vs Sham Acupuncture for Hand Osteoarthritis

Start date: April 26, 2022
Phase: N/A
Study type: Interventional

The investigators plan to conduct this multicentered, sham-controlled randomized clinical trial to evaluate the efficacy and safety of acupuncture for clinical symptomatic improvement of hand OA.

NCT ID: NCT05267054 Recruiting - Clinical trials for Refractory Diffuse Large B-cell Lymphoma

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Start date: April 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL)